en · de · es · pt
lab-handbook.peptides5388.com › Data › Background And Receptor Pharmacology — Worked Examples

Background And Receptor Pharmacology — Worked Examples

By Editorial Desk · published 2025-11-04 · last reviewed 2025-12-22 · Data

Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

SR9009 Handling and Quality Control

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Related pages on this site

Further detail

=== 20th century === 1901 Walter Kaufmann uses a mass spectrometer to measure the relativistic mass increase of electrons. 1905 J. J. Thomson begins his study of positive rays. 1906 Thomson is awarded the Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases" 1913 Thomson is able to separate particles of different mass-to-charge ratios. He separates the 20Ne and the 22Ne isotopes, and he correctly identifies the m/z = 11 signal as a doubly charged 22Ne particle. 1919 Francis Aston constructs the first velocity focusing mass spectrograph with mass resolving power of 130. 1922 Aston is awarded the Nobel Prize in chemistry "for his discovery, by means of his mass spectrograph, of isotopes, in a large number of non-radioactive elements, and for his enunciation of the whole-number rule." 1931

C-type natriuretic peptide (CNP) primarily interacts with NPR-B, which triggers an increase in the concentration of cGMP in the cell. This process can lead to several physiological effects, such as tissue remodeling, reduction of pulmonary hypertension and fibrosis, and stimulation of long bone growth. CNP is highly concentrated in vascular endothelial cells and plays a crucial role in regulating vascular tone through its vasodilatory action. Furthermore, CNP has been shown to have anti proliferative effects on vascular smooth muscle and an inhibitory effect on the migration of human coronary artery smooth muscle cells.

=== Interpretation of quantum mechanics === Jung influenced one philosophical interpretation (not the science) of quantum physics with the concept of synchronicity regarding some events as non-causal. That idea influenced the physicist Wolfgang Pauli (with whom, via a letter correspondence, Jung developed the notion of unus mundus in connection with the idea of nonlocality) and some other physicists.

Lee & Co as concrete contractor using a Lee's Mixer, an early example of concrete mixers used during construction on the Admiralty Pier. Further construction from 1897 onwards established the Eastern Arm of the current harbour, the Southern Breakwater and a further extension of the Admiralty Pier. During the First World War, a former cargo ship, the Spanish Prince, was deliberately sunk by the Admiralty close to the entrance to Dover Harbour to prevent German U-Boats from firing torpedoes into the harbour. During World War II, the remains of another ship, the War Sepoy, were sunk alongside the Spanish Prince.

Sources: en.wikipedia.org

Background from the literature

=== Research === Jennette's research encompasses clinical research based on evaluation of data obtained from patient medical records, clinical laboratory data, and pathologic evaluation of kidney biopsy specimens; basic research based on experimental investigations using specimens from patients or animal models of kidney disease; and translational research designed to apply (translate) basic research discoveries into improved diagnosis and treatment of disease in patients. Ronald J. Falk has been a colleague in many of his research works.

==== One-stepwise pyrolysis and two-stepwise pyrolysis for tobacco waste ==== Pyrolysis has also been used in trying to mitigate tobacco waste. One method was done where tobacco waste was separated into two categories, TLW (Tobacco Leaf Waste) and TSW (Tobacco Stick Waste). TLW was determined to be any waste from cigarettes and TSW was determined to be any waste from electronic cigarettes. Both TLW and TSW were dried at 80 °C for 24 hours and stored in a desiccator. Samples were grounded so that the contents were uniform. Tobacco Waste (TW) also contains inorganic (metal) contents, which was determined using an inductively coupled plasma-optical spectrometer. Thermo-gravimetric analysis was used to thermally degrade four samples (TLW, TSW, glycerol, and guar gum) and monitored under specific dynamic temperature conditions. About one gram of both TLW and TSW were used in the pyrolysis tests. During these analysis tests, CO2 and N2 were used as atmospheres inside of a tubular reactor that was built using quartz tubing. For both CO2 and N2 atmospheres the flow rate was 100 mL min−1. External heating was created via a tubular furnace. The pyrogenic products were classified into three phases. The first phase was biochar, a solid residue produced by the reactor at 650 °C. The second phase liquid hydrocarbons were collected by a cold solvent trap and sorted by using chromatography. The third and final phase was analyzed using an online micro GC unit and those pyrolysates were gases.

the sensitivity of the product to temperatures (high and low) and to time at temperatures the specific distribution system being used: the expected (and worst case) time and temperatures regulatory requirements the specific combination of packaging components and materials being used In specifying an insulated shipping container, the two primary characteristics of the material are its thermal conductivity or R-value, and its thickness. These two attributes will help determine the resistance to heat transfer from the ambient environment into the payload space. The coolant material load temperature, quantity, latent heat, and sensible heat will help determine the amount of heat the parcel can absorb while maintaining the desired control temperature. Combining the attributes from the insulator and coolant will allow analysis of expected duration of the insulated shipping container system. Testing of multi-component systems is needed.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network